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Abstract
Therapy has improved the survival of heart failure (HF) patients. However, many patients progress to advanced chronic HF (ACHF). We
propose a practical clinical definition and describe the characteristics of this condition.
Patients that are generally recognised as ACHF often exhibit the following characteristics: 1) severe symptoms (NYHA class III to IV);
2) episodes with clinical signs of fluid retention and/or peripheral hypoperfusion; 3) objective evidence of severe cardiac dysfunction, shown
by at least one of the following: left ventricular ejection fractionb30%, pseudonormal or restrictive mitral inflow pattern at Doppler-
echocardiography; high left and/or right ventricular filling pressures; elevated B-type natriuretic peptides; 4) severe impairment of functional
capacity demonstrated by either inability to exercise, a 6-minute walk test distanceb300 m or a peak oxygen uptakeb12–14 ml/kg/min; 5)
history of N1 HF hospitalisation in the past 6 months; 6) presence of all the previous features despite optimal therapy. This definition
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identifies a group of patients with compromised quality of life, poor prognosis, and a high risk of clinical events. These patients deserve
effective therapeutic options and should be potential targets for future clinical research initiatives.
© 2007 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
Keywords: Heart failure; Prognosis; Treatment
1. Introduction: changing clinical characteristics of
heart failure
Untreated heart failure (HF) is usually a progressive
syndrome, characterised by worsening of symptoms, un-
planned hospital admission due to acute decompensation,
development of complications (e.g. atrial arrhythmias) and
short life-span.Neurohormonal antagonists slow (but probably
rarely prevent) this progression, thereby delaying death and
avoiding or postponing hospital admissions [1,2]. The effect of
these drugs on patients' symptoms is less well defined and that
on functional capacity less convincing [3,4]. Implantable
cardioverter defibrillators (ICDs) also reduce the risk of
sudden death, which causes a larger proportion of deaths in
patients with mild HF, compared to those with severe HF. In a
subset of patients with more severe symptoms, cardiac
resynchronisation therapy (CRT) has recently been shown to
offer further improvements in symptoms, mortality and
morbidity.
Despite the beneficial effects of neurohormonal antago-
nists, ICDs and CRT, many patients eventually progress to an
advanced stage, characterised by severely limiting symp-
toms, marked haemodynamic impairment, frequent hospita-
lisations and high mortality. The extension of life provided
by neurohormonal antagonists or the direct effect of these
drugs (or a combination of both) also seems to have led to
certain complications (e.g. anaemia and renal dysfunction)
becoming a prominent feature in the growing number of
long-term survivors with HF. This emerging cohort of
patients with advanced chronic heart failure (ACHF)
represents a new population for which additional treatment
is required.
Despite its growing importance, not enough is known
about the characteristics and optimal management of ACHF.
The aims of this document are to propose a clinical definition
of this condition and to describe its main characteristics.
This summary is based on a full document, which includes
more background information and further references. The full
report is available on the HFA, ESC website, http://www.
escardio.org/bodies/associations/HFA/ and should be used
when in doubt or when further information is required.
2. Definition of ACHF
2.1. Definition
ACHF may be defined as a chronic, but not necessarily
irreversible, condition. Regardless of its aetiology, it is usually
characterised by all the features shown in Table 1 [5–10].
A comparison with other classifications of HF is shown in
Fig. 1.
2.2. Comparison with previous definitions
In 1998, Adams and Zannad first defined advanced HF as
requiring a resting LVejection fraction (LVEF)b30% andNew
York Heart Association (NYHA) functional class III to IVor a
peak oxygen uptake (VO2)b14 ml/kg/min. Additional criteria
were also provided [11]. We believe that this definition should
be updated. It does not incorporate subsequent advances both
in diagnosis (plasma BNP and NT-ProBNP) and in treatment
(beta-blocker therapy). We believe that its two main criteria
(LVEFb30%, and peak VO2b14 ml/kg/min) do not justify a
Table 1
Definition of ACHF
1. Severe symptoms of HF with dyspnoea and/or
fatigue at rest or with minimal exertion (NYHA
functional class III or IV)
2. Episodes of fluid retention (pulmonary and/or
systemic congestion, peripheral oedema) and/or of
reduced cardiac output at rest
(peripheral hypoperfusion)
3. Objective evidence of severe cardiac dysfunction,
shown by at least one of the following:
a) A low LVEF (b30%),
b) A severe abnormality of cardiac function on
Doppler-echocardiography with a pseudonormal
or restrictive mitral inflow pattern [5];
c) High LV filling pressures (mean PCWPN16 mm
Hg, and/or mean RAPN12 mm Hg by
pulmonary artery catheterisation) [6],
d) High BNP or NT-ProBNP plasma levels, in the
absence of non-cardiac causes.
4. Severe impairment of functional capacity shown
by one of the following:
a) Inability to exercise,
b) 6-MWT distanceb300 m [7] or less in females
and/or patients aged≥75 years [8]
c) peak VO2 b12 to 14 ml/kg/min [9,10]
5. History of ≥1 HF hospitalisation in the past
6 months
6. Presence of all the previous features despite
“attempts to optimise” therapy including diuretics,
inhibitors of the renin–angiotensin–aldosterone
system, and beta-blockers, unless these are poorly
tolerated or contraindicated, and CRT, when
indicated.
Abbreviations: ACHF, advanced chronic heart failure; NYHA, New York
Heart Association; LV, left ventricular; EF, ejection fraction; PCWP,
pulmonary capillary wedge pressure; RAP, right atrial pressure; BNP,
brain natriuretic peptide; NT, N-terminal; 6-MWT, 6-minute walk test; VO2,
oxygen consumption; CRT, cardiac resynchronisation therapy.
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diagnosis of advanced HF in the absence of a significant
clinical history. Patients with a peak VO2b14 ml/kg/min
[8,10], and/or inNYHAclass III to IV,with a LVEFb25%may
have an annual mortality rate of only 11–12% if euvolaemic
and treated with beta-blockers and ACE inhibitors [12,13].
Indeed, patients with a normal LVEF and a recent HF
hospitalisation may have a poorer prognosis [14,15].
More recently, an American expert group defined advanced
HF as a “state in which patients have significant cardiac
dysfunction with marked symptoms of dyspnoea, fatigue, or
symptoms relating to end-organ hypoperfusion at rest or with
minimal exertion despite maximal medical therapy” [16]. This
definition is similar to the one that we propose, but does not
include the criterion of a previous hospitalisation and does not
try to objectively assess the impairment of cardiac dysfunction
and functional capacity.
2.3. Comparison with other clinical presentations of heart
failure
2.3.1. Acute heart failure
Acute HF is a much broader entity than ACHF although
these patients may experience acute decompensation [17].
ACHF refers to a stage of the chronic syndrome whereas acute
HF refers to a single episode which may be the patient's first
presentation with HF (and even its only presentation, if the
cause is reversible) or an episode of deterioration occurring
during the chronic syndrome.
2.3.2. Refractory heart failure
Stage D refractory HF is a condition included in the ACC/
AHA guidelines [2] where it is defined by the presence of
marked symptoms at rest despite maximal medical therapy.
Our definition of ACHF includes stage D of the US clas-
sification (Fig. 1). Both refer to an advanced stage of the
disease in which the assessment of new therapies, like me-
chanical circulatory support, procedures to facilitate fluid
removal, or new parenteral agents, may be warranted [2].
2.3.3. End-stage HF
End-stage HF indicates an extremely advanced condition
where no improvement with conventional HF treatment is
possible and palliative care or “ventricular assist systems” or
heart transplantation (Htx) is indicated. This condition should
be distinguished from ACHF in which a certain degree of
reversibility may be present.
3. Clinical characteristics and diagnosis of ACHF
3.1. Symptoms and signs
Many patients with HF present for the first time with
severe symptoms and signs of marked volume overload or
even, acutely, pulmonary oedema. Avery low left ventricular
ejection fraction (LVEF) may be present. These patients
usually do not have ACHF. Treatment with diuretics, neuro-
hormonal antagonists (ACE inhibitors, beta-blockers, aldo-
sterone antagonists and angiotensin receptor blockers) and, in
certain cases, devices, will stabilise and improve the patient's
condition in most cases. If initially low, LVEF will also
usually increase. Thus, critical to the definition of ACHF is
persistence of severe symptoms, functional limitation and
cardiac dysfunction despite optimal therapy.
Only patients who remain symptomatic at rest (NYHA
class IV) or on minimal exertion (NYHA class III) despite
optimal drug and device therapy should be considered to
have ACHF. The definition of optimal therapy may change
over time as the patients' condition advances. For example
Fig. 1. Comparison between advanced heart failure and other classifications of heart failure. ⁎See Table 1 for further components of the definition of advanced
HF, including evidence of severe cardiac dysfunction, evidence of fluid retention/hypoperfusion, severely reduced functional capacity and hospitalisation for HF
within 6 months, despite optimum tolerated pharmacological and device treatment. ⁎⁎This document concerns chronic heart failure. Patients may move between
stages/classes in either direction but the natural history of heart failure is usually one of progressive worsening over time. ⁎⁎⁎Stage A = “at high risk of HF but
without structural heart disease or symptoms of HF” [2].
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spironolactone may not be indicated in a patient presenting
initially in NYHA class II but should be used, if tolerated, if
the patient progresses to NYHA class III.
The development of renal dysfunction and hypotension
may prevent the addition of new neurohormonal antagonists or
even necessitate the withdrawal of existing drugs. Diuretic
requirement may vary and careful titration is often required to
avoid volume overload and also volume depletion. A com-
bination of oral diuretic therapy and intermittent intravenous
treatment (with regular monitoring) may be needed. This
careful adjustment of therapy may allow symptom relief and
freedom from congestion for relatively long periods of time.
However, patients with ACHF are frequently hospitalised for
decompensated HF. As the patient's condition advances other
complications such as anaemia, generalised wasting (cardiac
cachexia) and renal failure may develop.
3.2. Systolic versus diastolic left ventricular dysfunction
Severe cardiac dysfunction is prerequisite for diagnosing
ACHF. Recent studies, however, have shown that up to 30%–
50% of patients admitted with acute HF may have preserved
LVEF [14,15,18–21]. Patients with preserved LVEF have a
high rate of rehospitalisation and a similar, or only slightly
lower, mortality, compared to patients with low LVEF [14,15].
Although their poor outcomes may be caused by a higher
prevalence of co-morbidities, some patients with normal
LVEF may progress to ACHF. However, it is important to
exclude non-cardiac causes of symptoms and reversible causes
of myocardial dysfunction, such as ischaemia or valvular heart
disease, in these patients. Therefore, the diagnosis should also
be based on the demonstration of high LV filling pressures,
high plasma levels of BNP or NT-ProBNP or, more recently,
on abnormalities of Doppler-echocardiographic indices of
diastolic function and/or LV long-axis function (Table 1) [1].
3.3. Echocardiographic assessment
3.3.1. Systolic function
The simplest index of global LV haemodynamic pump
function is LVEF. However, when used alone, it is an inad-
equate summary of global systolic function because, even
when LVEF is normal and in the presence of small LV
volumes, there may be significant LVrelaxation abnormalities,
longitudinal fiber dysfunction, as well as severe non-
uniformities. LVEF should, ideally, be reported together with
a ventricular volume — preferably end-systolic volume, in-
dexed for body surface area as well as with echocardiographic
long-axis measurements.
In some patients, LV global haemodynamic pump function
may be “preserved” (usually defined as an LVEF≥45–50%),
despite reduced LV long-axis systolic shortening [22,23],
because there is an accompanying increase in sphericity and in
radial systolic function. Thus, full echocardiographic char-
acterisation of LV systolic function should, ideally, include
measurement of LV long-axis function.
3.3.2. Diastolic function
The simplest assessment of LV filling is obtained by
recording the ratio of flow velocities across the mitral valve
during early diastole and during atrial filling (E/A ratio). This
ratio increases in HF as the left atrial pressure rises. When the
E/A ratio is N1 because of a high left atrial pressure, the
mitral inflow pattern is described as “pseudonormal”. This
can be distinguished from a true normal pattern if the E/A
ratio reverts to b1 with LV pre-load reduction. Additional
indices of diastolic function include the deceleration time
(DT) of early diastolic mitral inflow. In ACHF, the most
severe pattern of diastolic dysfunction is restrictive filling
which is characterised by a very high mitral E/A ratio (N2)
and a short mitral DT (b140 ms). This pattern reliably
predicts a poor prognosis, especially if it persists after pre-
load reduction [24].
Newer indices of diastolic function are useful in clinical
practice because they are less load dependent. Perhaps the
most useful of these is the ratio of the mitral E velocity to
the velocity of mitral annular motion during early diastole
recorded using pulsed Doppler-echocardiography (E/e′ or
E/Ve). This index has been validated extensively and
correlates well with LV filling pressure [25]. Other
methods are based on the study of pulmonary venous
flow. Recently, left atrial volume has emerged as a very
useful simple test since dilatation reflects a chronic increase
in pressure.
3.4. Natriuretic peptides and other biomarkers
BNP is released predominantly from the LV failing myo-
cardium and correlates with HF severity. BNP or NT-
proBNP may be useful to assess prognosis and to tailor
therapy. This hypothesis is currently being tested in
randomised trials [26,27].
Other plasma biomarkers related to inflammation or
neurohormonal activation may be used to assess prognosis in
patients with ACHF. Cardiac troponins are released by a
significant percentage of patients with HF of either
ischaemic or non-ischaemic aetiology, and may be important
for prognosis.
3.5. Exercise testing
By definition, patients with ACHF are in NYHA class III
or IV, implying severe functional limitation. The extent of
functional limitation can be further defined by formal
exercise testing.
3.5.1. Cardiopulmonary exercise (CPX) testing
Peak VO2, frequently adjusted for gender, age, and body
weight, and ventilatory response to exercise, usually mea-
sured as the slope of regression line relatingminute ventilation
(VE) to carbon dioxide production (VCO2) (VE–VCO2 slope)
[28–30] are the CPX derived parameters most often used in
clinical practice.
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CPX is commonly used to stratify the risk of death in
patients with HF and to identify candidates for Htx. Low peak
VO2 implies a poor outcome, independently of other risk
factors [8,10,28,31,32]. Nevertheless, its optimal cut-off point
for risk stratification is still debated [28,31,32]. It is generally
agreed that peak VO2N18 ml/kg/min identifies low risk
patients, whereas values ≤10 ml/kg/min indicate those with
severe functional impairment, poor outcome and a potential
indication for Htx [10,28,31]. A cut-off value of 14 ml/kg/min
has also been used to identify those with a potential indication
for Htx [8,10,28,33], although this threshold may no longer be
valid because it was derived from older studies in which
patients were not treated with beta-blockers, ICDs or CRT. A
lower value of 12 ml/kg/min has been suggested for the
indication to HTx in patients on beta-blocker treatment [10].
We also suggest using this lower value as a criterion for ACHF
in patients on beta-blocker treatment (Table 1). Additional
CPX derived indices (i.e. VE–VCO2 slope) may identify
patients at high risk of subsequent events. A combination of
peak VO2 with other clinical prognostic markers is also useful
[1,10,28,31].
3.5.2. Six-minute walk test
The 6-minute walk test (6-MWT) distance is another
measure of functional capacity which correlates with quality
of life and with more objective measures derived from maxi-
mal CPX [7,28,34]. A 6-MWT distanceb300 m implies
severe impairment, associatedwith a poor outcome, whereas a
distanceN500 m indicates moderately preserved exercise
capacity and a low risk of events [7,34]. However, age,
gender, and body mass index have an important influence on
6-MWTperformance [8,35] and thismust be consideredwhen
this test is used for the assessment of HF patients.
A significant number of patients withACHFmay not be able
to provide a 6-MWTor may have a contraindication to exercise
testing. This group has uniformly bad prognosis [28,31].
The value of the 6-MWTandCPXasmethods of evaluating
treatment in ACHF has not been assessed.
3.6. Hospitalisations
Hospitalisation rates, including number and duration of
admissions, are a very simple and important prognostic index
in patients with HF. Hospitalisation, especially due to worse-
ning HF, implies an unstable clinical course and a high short-
term probability of major events including death [19–
21,36,37].
3.7. Assessment of prognosis
The prognosis of patients with severe HF has improved
substantially in recent years but it remains poor. Useful
prognostic indicators are outlined in Table 2 [1,2,7,8,10,19–
21,24,28,31,32,37–40]. Signs of increased LV filling pressure
and/or of right ventricular dysfunction, assessed by Doppler-
echocardiography or cardiac catheterisation, are more impor-
tant in ACHF with a greater predictive power when these data
are collected after optimisation of therapy [6,24,41]. Risk-
stratification models have been developed and validated both
in patients referred forHtx and in those hospitalised forHF.Co-
morbidities, blood pressure and renal function are often
amongst the most important independent prognostic variables
[20,21,38–40,42]. These results can also be applied to patients
with ACHF.
4. Treatment of ACHF
4.1. Medical treatment
One key component of our definition of ACHF is that
patients are receiving guideline-recommended and individ-
ually optimised medical treatment. There is evidence that
neurohormonal antagonists are administered at lower rates
and at lower doses in patients with more severe HF [43] and
this may have a detrimental effect on prognosis [44]. It is
Table 2
Prognostic determinants in patients with ACHF
Demographic
▪ Advanced age
▪ Male gender
Clinical
▪ Frequent rehospitalisations
▪ Advanced NYHA class
▪ Intolerance to neurohormonal antagonists
▪ Persistent/relapsing signs of pulmonary or peripheral congestion
▪ Hypotension
▪ Co-morbidities (diabetes, renal failure, hepatic failure, anaemia, COPD, etc.)
Electrocardiography
▪ Resting tachycardia
▪ Wide QRS complex
Laboratory
▪ Hyponatraemia
▪ Renal insufficiency (BUN/serum creatinine)
▪ Anaemia
▪ Hepatic insufficiency
▪ Neurohormones (norepinephrine, endothelin…)
▪ Natriuretic peptides
▪ Cardiac myocyte necrosis markers (troponins)
▪ Inflammatory markers (CRP…)
Doppler-echocardiography and right heart catheterisation
▪ Low LV EF/increased LV ESVI
▪ Decreased LV long-axis systolic shortening
▪ Mitral regurgitation/increased left atrial volume
▪ Signs of increased LV filling pressure
▪ Low RV EF
▪ Increased pulmonary vascular resistance
Functional capacity
▪ Inability to perform an exercise test
▪ Low peak VO2 (ml/kg/min, percentage of predicted age, gender, body
weight adjusted values)
▪ Increased ventilatory response to exercise (VE/VCO2 slope)
▪ Low 6-minute walk test distance
Abbreviations: COPD, chronic obstructive pulmonary disease; LV, left
ventricular; EF, ejection fraction; ESVI, end-systolic volume index; RV,
right ventricular.
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therefore important to make every attempt to initiate and
up-titrate all indicated medications to the doses shown to be
effective.
4.1.1. ACE inhibitors
Patients with ACHF may be more likely to develop
symptomatic hypotension and/or renal insufficiency and such
intolerance to ACE inhibitors is an ominous prognostic sign
[45]. The benefits of these agents are so important that every
effort should be made to use them. Modest increases in serum
creatinine (e.g. an increase of ≤50% from baseline or to
≤266 μmol/l [3 mg/dl], which ever is the smaller) or
asymptomatic hypotension are not contraindications to con-
tinued treatment. Recommendations to minimize side effects
are given in guidelines [1,2] and practical guidance documents
[46].
4.1.2. Beta-blockers
The benefits of beta-blockers are at least as great in
patients with severe HF as in those with less advanced
disease [12,13].
The initiation of beta-blockers is contraindicated in patients
with acutely decompensated HF [1,2,17]. In patients who
develop acutely decompensated HF while on chronic beta-
blocker therapy, the dose of these agents may be reduced, or
they may be temporarily withdrawn, but treatment should be
re-started as soon as clinical conditions stabilise. Starting (or
re-starting) beta-blocker treatment during the HF hospitalisa-
tion is associated with a shorter titration phase and better
compliance [47].
In patients developing intolerance, thought to be due to
depressed LV systolic function, during initiation beta-blockers,
some authors advocate the use of concomitant inotropic
support although this is an unproven approach. Phosphodies-
terase inhibitors (PDE-I) and levosimendan are the drugs of
choice as their action, unlike dobutamine, is independent from
the beta-receptors [17,48].
4.1.3. Angiotensin receptor blockers (ARBs)
ARBs are a good alternative to ACE inhibitors in symp-
tomatic patients who do not tolerate them [1,2]. Based
on data from randomised trials [49,50], ARBs are also
indicated in addition to beta-blockers and ACE inhibitors
in patients who remain symptomatic, although careful
monitoring of potassium and renal function is mandatory
[1,2,46].
4.1.4. Aldosterone antagonists
Aldosterone antagonists are indicated in patients with
NYHA class III to IV HF caused by LV systolic dysfunction
[1,2,51]. They should be avoided in patients with severe renal
failure (serum creatinineN221 μmol/l [2.5 mg/dl]) and/or
hyperkalaemia (serum potassiumN5.0 mmol/l). Careful
monitoring of renal function and serum potassium levels is
mandatory. The effects of aldosterone antagonists on blood
pressure are smaller than ARBs.
4.1.5. Triple and quadruple combinations of neurohormonal
antagonists
The combination of three neurohormonal antagonists
should be attempted in all patients with ACHF. All patients
should receive an ACE inhibitor and beta-blocker unless there
is intolerance. Either an ARB or an aldosterone antagonist
should then be added. There is no evidence regarding which
are the preferred agents to use in combination. Both spirono-
lactone and candesartan have demonstrated benefits on
mortality when added to an ACE inhibitor [50,51].
The use of four neurohormonal antagonists (i.e. ACE
inhibitor, beta-blocker, ARB and aldosterone antagonist) is
not evidence-based and the safety and efficacy of these
agents used together are uncertain. If used, careful monitoring
of blood pressure, renal function and serum potassium is
mandatory.
4.1.6. Diuretics
High doses of loop diuretics are often necessary in the
patients with ACHF. When used intravenously, continuous
infusion of loop diuretics is more efficient than bolus therapy
[17]. The combination of a thiazide or spironolactone with
loop diuretics has been proposed to overcome diuretic resis-
tance [17]. Metolazone has been advocated as an alternative to
thiazide diuretics as it remains effective at low glomerular
filtration rates [17].
Since high doses of diuretics are associated with adverse
effects, including dehydration, renal dysfunction, hypoka-
laemia and gout, the need for continued high dose treatment
should be reconsidered once signs of congestion have re-
solved. Patients should then be maintained at the lowest dose
that can keep them clinically stable and free of congestion (at
their “dry weight”) [1,2,17,46]. Careful monitoring of renal
function and serum electrolytes is mandatory in any patient,
but particularly important when high doses or combinations
of diuretics are used.
Ultrafiltration has been shown to be a safe and effective
treatment to reduce congestion in patients with decompen-
sated HF and diuretic resistance [52].
4.1.7. Nitrates
In ACHF, oral nitrates can be used to relieve concomitant
angina but only have a long-term benefit on survival and
hospitalisation when used in conjunction with hydralazine
[53]. In the African-American Heart Failure Trial, a fixed
dose combination of isosorbide dinitrate and hydralazine
reduced all-cause mortality and HF hospitalisations and
improved quality of life, compared to placebo, in 1050 black
patients with NYHA class III or IV HF on optimal medical
treatment including diuretics and neurohormonal antagonists
[54].
4.1.8. Digoxin
Digoxin is indicated in patients with HF and concomitant
atrial fibrillation. In the Digitalis Investigation Group (DIG)
trial, digoxin reduced HF hospitalisations but not mortality
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in HF patients in sinus rhythm treated with diuretics and
ACE inhibitors. As frequent hospitalisations are among the
hallmarks of ACHF, digoxin is indicated in most patients
with ACHF. Further analyses have indicated different effects
of digoxin on mortality, with a reduction versus placebo at
low serum digoxin levels, and no effect at higher plasma
levels [55]. However, since renal impairment is frequent in
ACHF, daily dosage should be adapted accordingly.
4.1.9. Other inotropic agents
Temporary inotropic support using intravenous sympa-
thomimetic agents, PDE-I or levosimendan, can be consid-
ered in patients who have evidence of severely reduced
peripheral perfusion with or without pulmonary congestion
[1,2,17]. Despite short-term haemodynamic improvement,
these agents may have an adverse effect on mortality [56]
and cause supraventricular and ventricular tachyarrhythmias
[57]. Thus, they should be administered only when indicated
(signs of peripheral hypoperfusion), at the lowest effective
doses and for the shortest duration of time as possible [17].
4.1.10. Anti-platelet and anti-thrombotic agents
Atrial fibrillation is more common in patients with more
severe HF and, in the absence of a contraindication, warfarin
should be given to reduce the risk of thromboembolism [58].
The use of warfarin in other patients is not evidence-based
although most clinicians will also use warfarin in patients
shown to have left ventricular thrombus on an imaging study.
Aspirin should be considered in patients with coronary
artery disease or with atrial fibrillation and contraindications
to oral anticoagulation [58]. Some authors take the view that
there is no robust evidence supporting long-term use of
aspirin in patients with HF and suggest that it may even have
detrimental effects, possibly by antagonising the effect of
vasodilator prostaglandins and the actions of ACE inhibitors.
Although this view is controversial, there is evidence that
patients treated with aspirin may have an increased risk of
hospital admission due to worsening HF [59,60].
4.1.11. Cardiac resynchronisation therapy (CRT)
The indications to implantable cardioverter defibrillators
and CRT have been thoroughly discussed in guidelines [1,2].
CRT,with [61] orwithout [62] combined ICD, has been shown
to reduce mortality and hospitalisations and improve symp-
toms and quality of life in patients with NYHA class III to IV
HF, reduced LVEF and wide QRS duration. It should therefore
be considered inACHF patients with these characteristics. The
importance of mechanical dyssynchrony, independently from
QRS duration, remains to be investigated.
4.1.12. Implantable cardioverter defibrillator (ICD)
As HF progresses the risk of death from pump failure,
relative to sudden, presumed arrhythmic, death increases.
There is also evidence that the benefit of an ICD is less in
patients with advanced HF. In the SCD-HeFT trial there was
statistically significant heterogeneity in the effect of ICD
therapy according to baseline NYHA class, with no reduction
inmortality in patients in functional class III [63]. It is however
possible that this result was related to the lower number of
patients in NYHA class III. Though underpowered, the
Defibrillators in Non-Ischemic Cardiomyopathy Treatment
Evaluation (DEFINITE) trial showed opposite results, with the
largest reduction in mortality in NYHA class III patients [64].
Probably the most important factor determining the
indication for ICD implantation in a patient with advanced
HF is her/his life expectancy. Analyses of controlled trials
have shown the time dependency of the beneficial effects of
ICDs on mortality, with a lack of benefit in the first months
after implantation and an exponential rise in benefit thereafter
reaching a peak after 3 years [65]. Accordingly, economic
analyses have shown that it may need up to 6–7 years of
follow-up to be cost effective [66,67]. Thus, ICDs may not be
indicated in patients with ACHF and a predicted short life
expectancy. This approach is, however, not considered in
current guidelines and not evidence based.
In a patient with an ICD who progresses to terminal heart
failure, the physician, patient and family/carers may decide
to inactivate the device.
4.1.13. New agents
The potential role and the risk/benefit ratio of some newer
agents have not yet been established. The vasodilator
nesiritide, a recombinant human B-type natriuretic peptide,
improved haemodynamics and symptoms in patients with
acute HF but its long-term effects have not been assessed
sufficiently. It is approved for treatment of acutely decom-
pensated HF in US but not in Europe [17]. Other natriuretic
peptides, like urodilatin, are currently under investigation [68].
Tolvaptan is a selective antagonist of vasopressin V2
receptors. It increases water permeability of the renal col-
lecting tubules, thereby promoting excretion of retained water
and weight loss and normalizing hypoosmolar hyponatraemia.
Its efficacy on symptoms and clinical course is currently under
investigation [69].
Adenosine A1 receptor antagonists may increase diuresis
and improve renal function in patients with ACHF [70].
Drugs that block lipid oxidation may produce a preferential
shift to intracellular glucose utilization, which is energetically
more efficient. Some of these drugs, perhexilene [71] and
trimetazidine [72], might have favourable effects in patients
with severe HF.
Statins have many potentially beneficial effects in patients
with ACHF. Their effects on outcomes are currently being
tested in large multicenter trials [73,74].
4.2. Treatments that should be discontinued
Discontinuation of unnecessary hypotensive agents such as
nitrates, calcium channel blockers and alpha adrenoceptor
antagonists, can facilitate introduction and/or up-titration of
neurohormonal antagonists. A number of medicines have
either demonstrated adverse effects in patientswithHFor there
690 M. Metra et al. / European Journal of Heart Failure 9 (2007) 684–694
Au
th
or
's 
  p
er
so
na
l   
co
py
are theoretical reasons for caution. These effects are mediated
by a variety of mechanisms, including fluid retention, reduced
contractility, potential pro-arrhythmic effects, direct cardio-
toxicity and drug–drug interactions [1,2,75].
4.3. Disease management programmes
Disease management programmes improve the care and
outcomes of patients with ACHF. Their key components are a
multidisciplinary approach including adequate education for
patients and carers, frequent monitoring of clinical status, and
careful assessment of patient's compliance to therapy. Disease
management programmes have been consistently shown to be
associated with a reduction in hospitalisations and, in some
studies and meta-analyses, mortality [1,2,16,76]. The ESC
guidelines give HF management programmes a strong
recommendation [1].
4.4. Surgical strategies
4.4.1. Heart transplantation (Htx)
Htx is indicated in patients with severe symptoms of HF
for whom no additional medical or surgical treatment is
possible, including CRT, and in whom life expectancy is less
than one year. Contraindications to heart transplantation
have been summarised in recent guidelines [1,2,10].
4.4.2. Mechanical support
Mechanical circulatory assist devices were developed to
sustain the circulation in patients awaiting Htx (bridge to
transplant) [77]. Implantable LVassist devices (LVADs) allow
many patients to survive until the time of transplantation, and
pre-operative recovery of haemodynamic and nutritional status
improves post-operative survival. Occasionally, LVADs may
improve myocardial function so effectively that the device can
be removed and transplantation is no longer required (bridge to
recovery). In selected patients with end-stage HF due to
idiopathic dilated cardiomyopathy, weaning from a LVAD is a
clinical option with good long-term results. The ultimate goal
of the implantable LVAD is to provide an alternative to cardiac
transplantation (destination therapy) [78].
4.4.3. Other surgical interventions
Revascularization is presently only indicated for symp-
tomatic myocardial ischaemia and can be performed success-
fully in patients whose LVEF is ≤30%, with a low hospital
mortality [79]. Until the res lts of ongoing randomised trials
are reported [80], revascularization is not indicated for other
putative reasons such as “hibernating myocardium”. Treat-
ment of secondary mitral regurgitation by undersized mitral
annuloplasty is another intervention being tested in a
randomised trial. This is also the case for surgical LV res-
toration, which reduces LV volume and restores its elliptical
shape, and can be accompanied by revascularization. Myocar-
dial restraint devices are also currently under investigation
[81].
4.5. End of life
The goal of end-of-life care is to control debilitating
symptoms and manage distress. In The Regional Study of
Care for the Dying, the most commonly reported symptoms
in the months prior to death were pain, dyspnoea, low mood,
sleeplessness, and anxiety [82]. Agents which may help
palliate symptoms, include opiates, inotropes and diuretics.
Although health care systems and laws differ from
country to country, issues surrounding end-of-life care for
patients with HF are similar and deserve attention. The
anticipated course of the disease (including prognosis),
treatment options (including resuscitation and ICD inacti-
vation) and planning of treatment and care (including
hospice care, if available) should be discussed with the
patient and family before he/she becomes too ill to
participate in decision-making. Advance directives are
decisions about desired treatments made by individuals
and shared with loved ones and health care providers,
although any decisions made should be reassessed at regular
intervals as they may change over time [16,83].
5. Priorities for clinical research
This position statement identifies many questions, that are
as yet unanswered. Much remains unknown about the epi-
demiology, diagnosis, prognosis, and treatment of patients
with ACHF. Particular areas that may merit further investiga-
tion are shown in Table 3.
Table 3
Priorities for clinical research in ACHF
A. Epidemiology
▪ Incidence and prevalence
▪ Prognosis
▪ Prognostic variables
B. Role of LV systolic dysfunction
▪ Clinical presentation, pathophysiology, and outcome of advanced HF
in patients with either poor LV systolic function or a normal EF
C. Role of plasma biomarkers
▪ Utility of measuring natriuretic peptides for diagnosis and prognosis
▪ Utility of measuring other neurohormones or biomarkers
▪ Comparison with clinical assessment
D. Prognosis
▪ Search for new prognostic indicators
▪ Comparison of the relative prognostic value of clinical, laboratory,
echocardiographic and exercise capacity indices
▪ Comparison of the value of repeated measurements of these indices for
prognosis and optimising medical treatment
E. Treatment
▪ Randomised controlled trials of novel pharmacologic and device
interventions
F. End-of-life care
▪ Patients preferences for end-of life care and experiences of having
advanced heart failure (symptom perceptions, quality of life, thoughts
about death and dying)
▪ Controlled trials evaluating the effects of combining palliative care and
specialist follow-up in advanced and end-stage heart failure
691M. Metra et al. / European Journal of Heart Failure 9 (2007) 684–694
Au
th
or
's 
  p
er
so
na
l   
co
py
Acknowledgement
We wish to thank Inge Torfs for her assistance in the
preparation of the manuscript.
References
[1] Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis
and treatment of chronic heart failure: executive summary (update
2005): the Task Force for the Diagnosis and Treatment of Chronic
Heart Failure of the European Society of Cardiology. Eur Heart J
2005;26:1115–40.
[2] Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline
update for the diagnosis and management of chronic heart failure in the
adult-summary article. A report of the American College of
Cardiology/American Heart Association. Task Force on Practice
Guidelines (Writing Committee to Update the 2001 Guidelines for
the Evaluation and Management of Heart Failure). J Am Coll Cardiol
2005;46:1116–43.
[3] Abdulla J, Abildstrom SZ, Christensen E, Kober L, Torp-Pedersen C.
A meta-analysis of the effect of angiotensin-converting enzyme
inhibitors on functional capacity in patients with symptomatic left
ventricular systolic dysfunction. Eur J Heart Fail 2004;6:927–35.
[4] Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L.
Differential effects of beta-blockers in patients with heart failure: a
prospective, randomized, double-blind comparison of the long-term
effects of metoprolol versus carvedilol. Circulation 2000;102:546–51.
[5] European Study Group on Diastolic Heart Failure. How to diagnose
diastolic heart failure. Eur Heart J 1998;19:990–1003.
[6] Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of
congestive heart failure and pulmonary artery catheterization effec-
tiveness: the ESCAPE trial. JAMA 2005;294:1625–33.
[7] Bittner V, Weiner DH, Yusuf S, et al. Prediction of mortality and
morbidity with a 6-minute walk test in patients with left ventricular
dysfunction. SOLVD Investigators. JAMA 1993;270:1702–7.
[8] Ingle L, Rigby AS, Nabb S, Jones PK, Clark AL, Cleland JG. Clinical
determinants of poor six-minute walk test performance in patients with
left ventricular systolic dysfunction and no major structural heart
disease. Eur J Heart Fail 2006;8:321–5.
[9] O'Neill JO, Young JB, Pothier CE, LauerMS. Peak oxygen consumption
as a predictor of death in patients with heart failure receiving β-blockers.
Circulation 2005;111:2313–8.
[10] Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart
transplantation: International Society for Heart and Lung Transplan-
tation guidelines for the care of cardiac transplant candidates—2006.
J Heart Lung Transplant 2006;25:1024–42.
[11] Adams Jr KF, Zannad F. Clinical definition and epidemiology of
advanced heart failure. Am Heart J 1998;135(6 Pt 2 Su):S204–15.
[12] Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival
in severe chronic heart failure. N Engl J Med 2001;344:1651–8.
[13] Goldstein S, Fagerberg B, Hjalmarson A, et al. Metoprolol controlled
release/extended release in patientswith severe heart failure: analysis of the
experience in the MERIT-HF study. J Am Coll Cardiol 2001;38: 932–8.
[14] Lenzen MJ, Scholte op Reimer WJM, Boersma E, et al. Differences
between patients with a preserved and a depressed left ventricular
function: a report from the EuroHeart Failure Survey. Eur Heart J
2004;25:1214–20.
[15] Aurigemma GP. Diastolic heart failure—a common and lethal
condition by any name. N Engl J Med 2006;355:308–10.
[16] Goodlin SJ,Hauptman PJ,ArnoldR, et al. Consensus statement: palliative
and supportive care in advanced heart failure. J Card Fail 2004;10: 200–9.
[17] Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the
guidelines on the diagnosis and treatment of acute heart failure: the Task
Force on Acute Heart Failure of the European Society of Cardiology.
Eur Heart J 2005;26:384–416.
[18] Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey
programme— a survey on the quality of care among patients with heart
failure in Europe. Part 1: patient characteristics and diagnosis. EurHeart
J 2003;24:442–63.
[19] Rudiger A, Harjola V-P, Muller A, et al. Acute heart failure: clinical
presentation, one-year mortality and prognostic factors. Eur J Heart
Fail 2005;7:662–70.
[20] Tavazzi L, Maggioni AP, Lucci D, et al. Nationwide survey on acute
heart failure in cardiology ward services in Italy. Eur Heart J 2006;27:
1207–15.
[21] Zannad F, Mebazaa A, Juilliére Y, et al. Clinical profile, contemporary
management and one-year mortality in patients with severe acute heart
failure syndromes: the EFICA study. Eur J Heart Fail 2006;8:697–705.
[22] Petrie MC, Caruana L, Berry C, McMurray JJ. “Diastolic heart failure”
or heart failure caused by subtle left ventricular systolic dysfunction?
Heart 2002;87:29–31.
[23] Vinereanu D, Nicolaides E, Tweddel AC, Fraser AG. “Pure” diastolic
dysfunction is associated with long-axis systolic dysfunction. Implica-
tions for the diagnosis and classification of heart failure. Eur J Heart
Fail 2005;7:820–8.
[24] Pozzoli M, Traversi E, Cioffi G, Stenner R, Sanarico M, Tavazzi L.
Loading manipulations improve the prognostic value of Doppler
evaluation of mitral flow in patients with chronic heart failure.
Circulation 1997;95:1222–30.
[25] Ommen S, Nishimura RA, Appleton CP, et al. Clinical utility of
Doppler echocardiography and tissue Doppler imaging in the
estimation of left ventricular filling pressures: a comparative simulta-
neous Doppler-catheterization study. Circulation 2000;102:1788–94.
[26] Richards AM, Troughton R, Lainchbury J, Doughty R, Wright S.
Guiding and monitoring of heart failure therapy with NT-ProBNP:
concepts and clinical studies. J Card Fail 2005;11(5 Suppl):S34–7.
[27] Shah MR, Claise KA, Bowers MT, et al. Testing new targets of therapy
in advanced heart failure: the design and rationale of the Strategies for
Tailoring Advanced Heart Failure Regimens in the Outpatient Setting:
BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE
(STARBRITE) trial. Am Heart J 2005;150:893–8.
[28] Working Group on Cardiac Rehabilitation and Exercise Physiology,
Working Group on Heart Failure of the European Society of Cardiology.
Recommendations for exercise testing in chronic heart failure patients.
Eur Heart J 2001;22:37–45.
[29] Chua TP, Ponikowski P, Harrington D, et al. Clinical correlates and
prognostic significance of the ventilatory response to exercise in chronic
heart failure. J Am Coll Cardiol 1997;29:1585–90.
[30] Kleber FX, Vietzke G, Wernecke KD, et al. Impairment of ventilatory
efficiency in heart failure: prognostic impact. Circulation 2000;101:
2803–9.
[31] Corra U, Mezzani A, Bosimini E, Giannuzzi P. Cardiopulmonary
exercise testing and prognosis in chronic heart failure: a prognosticat-
ing algorithm for the individual patient. Chest 2004;126:942–50.
[32] Myers J, Gullestad L, Vagelos R, et al. Clinical, hemodynamic, and
cardiopulmonary exercise test determinants of survival in patients referred
for evaluation of heart failure. Ann Intern Med 1998;129: 286–93.
[33] ManciniDM,EisenH,KussmaulW,Mull R, Edmunds Jr LH,Wilson JR.
Value of peak exercise oxygen consumption for optimal timing of cardiac
transplantation in ambulatory patients with heart failure. Circulation
1991;83:778–86.
[34] Faggiano P, D'Aloia A, Gualeni A, Brentana L, Dei Cas L. The 6
minute walking test in chronic heart failure: indications, interpretation
and limitations from a review of the literature. Eur J Heart Fail 2004;6:
687–91.
[35] Olsson LG, Swedberg K, Clark AL, Witte KK, Cleland JG. Six minute
corridor walk test as an outcome measure for the assessment of
treatment in randomized, blinded intervention trials of chronic heart
failure: a systematic review. Eur Heart J 2005;26:778–93.
[36] Dickstein K, Gleim G, Snapinn S, James M, Kjekshus J. The impact of
morbid events on survival following hospitalisation for complicated
myocardial infarction. Eur J Heart Fail 2006;8:74–80.
692 M. Metra et al. / European Journal of Heart Failure 9 (2007) 684–694
Au
th
or
's 
  p
er
so
na
l   
co
py
[37] Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure
Survey II (EHFS II): a survey on hospitalized acute heart failure
patients: description of population. Eur Heart J 2006;27:2725–36.
[38] Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting
mortality among patients hospitalized for heart failure: derivation and
validation of a clinical model. JAMA 2003;290:2581–7.
[39] Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and
morbidity in patients with chronic heart failure. Eur Heart J 2006;27:
65–75.
[40] Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure
Model: prediction of survival in heart failure. Circulation 2006;113:
1424–33.
[41] Gavazzi A, Ghio S, Scelsi L, et al. Response of the right ventricle to
acute pulmonary vasodilation predicts the outcome in patients with
advanced heart failure and pulmonary hypertension. Am Heart J
2003;145: 310–6.
[42] Fonarow GC, Adams Jr KF, Abraham WT, Yancy CW, Boscardin WJ.
ADHERE Scientific Advisory Committee, Study Group, and Inves-
tigators. Risk stratification for in-hospital mortality in acutely
decompensated heart failure: classification and regression tree analysis.
JAMA 2005;293:572–80.
[43] Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure
Survey programme—a survey on the quality of care among patients
with heart failure in Europe. Part 2: treatment. Eur Heart J 2003;24:
464–74.
[44] Komajda M, Lapuerta P, Hermans N, et al. Adherence to guidelines is a
predictor of outcome in chronic heart failure: the MAHLER survey.
Eur Heart J 2005;26:1653–9.
[45] Kittleson M, Hurwitz S, Shah MR, et al. Development of circulatory-
renal limitations to angiotensin-converting enzyme inhibitors identifies
patients with severe heart failure and early mortality. J Am Coll Cardiol
2003;41:2029–35.
[46] McMurray J, Cohen-Solal A, Dietz R, et al. Practical recommendations
for the use of ACE inhibitors, beta-blockers, aldosterone antagonists
and angiotensin receptor blockers in heart failure: putting guidelines
into practice. Eur J Heart Fail 2005;7:710–21.
[47] Gattis WA, O'Connor CM, Gallup DS, et al. Predischarge initiation of
carvedilol in patients hospitalized for decompensated heart failure
(IMPACT-HF trial). J Am Coll Cardiol 2004;43:1534–41.
[48] Metra M, Nodari S, D'Aloia A, et al. Beta-blocker therapy influences
the hemodynamic response to inotropic agents in patients with heart
failure: a randomized comparison of dobutamine and enoximone before
and after chronic treatment with metoprolol or carvedilol. J Am Coll
Cardiol 2002;40:1248–58.
[49] Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial
Investigators. A randomized trial of the angiotensin-receptor blocker
valsartan in chronic heart failure. N Engl J Med 2001;345:1667–75.
[50] McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in
patients with chronic heart failure and reduced left-ventricular systolic
function taking angiotensin-converting-enzyme inhibitors: the
CHARM-Added trial. Lancet 2003;362:767–71.
[51] Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on
morbidity andmortality in patients with severe heart failure. Randomized
Aldactone Evaluation Study Inves igators. N Engl J Med 1999;341:
709–17.
[52] Costanzo MR, Saltzberg M, O'Sullivan J, Sobotka P. Early
ultrafiltration in patients with decompensated heart failure and diuretic
resistance. J Am Coll Cardiol 2005;46:2047–51.
[53] Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy
on mortality in chronic congestive heart failure. Results of a Veterans
Administration Cooperative Study. N Engl J Med 1986;314:1547–52.
[54] Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide
dinitrate and hydralazine in blacks with heart failure. N Engl J Med
2004;351:2049–57.
[55] Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in
mortality and hospitalisation in heart failure: a comprehensive post hoc
analysis of the DIG trial. Eur Heart J 2006;27:178–86.
[56] Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness
and relative effectiveness of intravenous inotropic drugs acting through
the adrenergic pathway in patients with heart failure—a meta-
regression analysis. Eur J Heart Fail 2002;4:515–29.
[57] Cuffe MS, Califf RM, Adams Jr KF, et al. Short-term intravenous
milrinone for acute exacerbation of chronic heart failure: a randomized
controlled trial. JAMA 2002;287:1541–7.
[58] Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006
guidelines for the management of patients with atrial fibrillation —
executive summary. A report of the American College of Cardiology/
American Heart Association Task Force on practice guidelines and the
European Society of Cardiology Committee for Practice Guidelines
(Writing Committee to revise the 2001 guidelines for the management
of patients with atrial fibrillation). Eur Heart J 2006;27:1979–2030.
[59] Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and
cumulative meta-analyses from the American College of Cardiology:
WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-
US, RIO-Lipids and cardiac resynchronisation therapy in heart failure.
Eur J Heart Fail 2004;6:501–8.
[60] Massie BM. Aspirin use in chronic heart failure: what should we
recommend to the practitioner? J Am Coll Cardiol 2005;46:963–6.
[61] Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization
therapy with or without an implantable defibrillator in advanced
chronic heart failure. N Engl J Med 2004;350:2140–50.
[62] Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac
resynchronization on morbidity and mortality in heart failure. N Engl
J Med 2005;352:1539–49.
[63] Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable
cardioverter–defibrillator for congestive heart failure. N Engl J Med
2005;352: 225–37.
[64] Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator
implantation in patients with nonischemic dilated cardiomyopathy.
N Engl J Med 2004;350:2151–8.
[65] Salukhe TV, Dimopoulos K, Sutton R, Coats AJ, PiepoliM, Francis DP.
Life-years gained from defibrillator implantation: markedly nonlinear
increase during 3 years of follow-up and its implications. Circulation
2004;109: 1848–53.
[66] Feldman AM, de Lissovoy G, Bristow MR, et al. Cost effectiveness of
cardiac resynchronization therapy in the Comparison of Medical
Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION)
trial. J Am Coll Cardiol 2005;46:2311–21.
[67] Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert JC, Cleland JG.
The long-term cost-effectiveness of cardiac resynchronization therapy
with or without an implantable cardioverter–defibrillator. Eur Heart J
2007;28:42–51.
[68] Cleland JGF, Coletta AP, Lammiman M, et al. Clinical trials update
from the European Society of Cardiology meeting 2005: CARE-HF
extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-
2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. Eur J Heart
Fail 2005;7:1070–5.
[69] Gheorghiade M, Orlandi C, Burnett JC, et al. Rationale and design of
the multicenter, randomized, double-blind, placebo-controlled study to
evaluate the Efficacy of Vasopressin antagonism in Heart Failure:
Outcome Study with Tolvaptan (EVEREST). J Card Fail 2005;11:
260–9.
[70] Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1
adenosine receptor antagonist, protects against the decline in renal
function observed with diuretic therapy. Circulation 2002;105:1348–53.
[71] Lee L, Campbell R, Scheuermann-Freestone M, et al. Metabolic
modulation with perhexiline in chronic heart failure: a randomized,
controlled trial of short-term use of a novel treatment. Circulation
2005;112: 3280–8.
[72] Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of
trimetazidine, a partial free fatty acid oxidation inhibitor, in patients
with heart failure. J Am Coll Cardiol 2006;48:992–8.
[73] Tavazzi L, Tognoni G, Franzosi MG, et al. Rationale and design of the
GISSI heart failure trial: a large trial to assess the effects of n-3
693M. Metra et al. / European Journal of Heart Failure 9 (2007) 684–694
Au
th
or
's 
  p
er
so
na
l   
co
py
polyunsaturated fatty acids and rosuvastatin in symptomatic congestive
heart failure. Eur J Heart Fail 2004;6:635–41.
[74] Kjekshus J, Dunselman P, Blideskog M, et al. A statin in the treatment
of heart failure? Controlled rosuvastatin multinational study in heart
failure (CORONA): study design and baseline characteristics. Eur J
Heart Fail 2005;7:1059–69.
[75] Scottish Intercollegiate Guidelines Network— SIGN. 95 Management
of chronic heart failure. A national clinical guideline. Available at
http://www.sign.ac.uk/pdf/sign95.pdf.
[76] McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary
strategies for the management of heart failure patients at high risk for
admission: a systematic review of randomized trials. J Am Coll Cardiol
2004;44:810–9.
[77] Stevenson LW, Rose EA. Left ventricular assist devices: bridges to
transplantation, recovery, and destination for whom? Circulation
2003;108:3059–63.
[78] Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left
ventricular assistance for end-stage heart failure. N Engl J Med
2001;345:1435–43.
[79] Elefteriades JA, Tolis Jr G, Levi E, et al. Coronary artery bypass
grafting in severe left ventricular dysfunction: excellent survival with
improved ejection fraction and functional state. J Am Coll Cardiol
1993;22:1411.
[80] Buckberg JD. Questions and answers about the STICH trial: a different
perspective. J Thorac Cardiovasc Surg 2005;130:245–9.
[81] Mann DL. Cardiac remodeling as therapeutic target: treating heart
failure with cardiac support devices. Heart Fail Rev 2005;10:93–4.
[82] Levenson JW, McCarthy EP, Lynn J, Davis RB, Phillips RS. The last
six months of life for patients with congestive heart failure. J Am
Geriatr Soc 2000;48:S101–9.
[83] Freeborne N, Lynn J, Desbiens NA. Insights about dying from the
SUPPORT project. The Study to Understand Prognoses and Preferences
for Outcomes and Risks of Treatments. J Am Geriatr Soc 2000;48:
S199–205.
694 M. Metra et al. / European Journal of Heart Failure 9 (2007) 684–694
